SCHEMBL6944295

SCHEMBL6944295

O=C(NCc1ccccc1)c1cc([N+](=O)[O-])ccc1F

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.58
KMT2A Q03164 4/20 0.58
CYP1A2 P05177 1/20 0.58
CYP3A4 P08684 1/20 0.58
HPGD P15428 1/20 0.58
CYP2C19 P33261 1/20 0.58
GAA P10253 2/20 0.57
MAPT P10636 2/20 0.57
AKR1C3 P42330 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.52
ALOX15 P16050 1/20 0.52
HSD17B10 Q99714 1/20 0.52
ALDH1A1 P00352 2/20 0.51
FFAR1 O14842 1/20 0.51
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
GABRP O00591 1/20 0.51
GABRD O14764 1/20 0.51
GABRA1 P14867 1/20 0.51
GABRB1 P18505 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6946378 0.93 MEN1 (0.52) MEN1KMT2ACYP1A2CYP3A4HPGD
SCHEMBL6942032 0.90 FFAR1 (0.58) MEN1KMT2ACYP1A2CYP3A4HPGD
SCHEMBL6942084 0.87 MMP13 (0.57) MEN1KMT2ACYP3A4MAPTSMN1; SMN2
SCHEMBL6941766 0.87 MEN1 (0.54) MEN1KMT2ACYP1A2CYP3A4HPGD
SCHEMBL6940724 0.86 MEN1 (0.61) MEN1KMT2ACYP1A2CYP3A4HPGD
SCHEMBL6939622 0.86 RXFP1 (0.64) GAAMAPTSMN1; SMN2ALDH1A1
SCHEMBL9164075 0.85 MEN1 (0.60) MEN1KMT2ACYP1A2CYP3A4HPGD
SCHEMBL9162780 0.84 MEN1 (0.58) MEN1KMT2ACYP1A2CYP3A4HPGD
SCHEMBL6939616 0.84 MEN1 (0.51) MEN1KMT2ACYP1A2CYP3A4HPGD
SCHEMBL6943714 0.84 HPGD (0.46) MEN1KMT2ACYP1A2CYP3A4HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1080069-B1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO (JP) 2003-03-19 EP disclosed
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-12-19 US disclosed
US-6384080-B1 TREATMENT AND/OR PREVENTION OF CERTAIN CARDIOVASCULAR DISORDERS, UROGENITAL DISORDERS, RESPIRATORY SYSTEM DISORDERS, DISORDERS OF GUT MOTILITY, SEXUAL DISORDERS, DIABETIC COMPLICATIONS, URTICARIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-05-07 US disclosed
CN-1305454-A Anthranilic acid derivatives as inhibitors of CGMP phosphodiesterase FUJISAWA PHARMACEUTICAL CO (JP) 2001-07-25 CN disclosed
EP-1080069-A1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-03-07 EP disclosed
WO-1999054284-A1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase PDE3A, PDE2A, PDE5A MEN1 2660/4885KMT2A 1991/4885CYP1A2 137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.